Open this publication in new window or tab >>Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden..
Örebro Univ, IRiSC Inflammatory Response & Infect Susceptibil, Örebro, Sweden.;Örebro Univ, Fac Med & Hlth, Dept Clin Res Lab, Örebro, Sweden..
Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Gothenburg, Sweden..
Örebro Univ, Sch Med Sci, Örebro, Sweden..
Örebro Univ, Sch Med Sci, Örebro, Sweden..
Karolinska Inst, Dept Med, Clin Epidemiol Unit, Solna, Sweden.;LUM Univ, Dept Med & Surg, Casamassima, Italy.;CIC BioGUNE BRTA, Gastrointestinal Genet Lab, Derio, Spain.;Basque Fdn Sci, Ikerbasque, Bilbao, Spain..
Linköping Univ, Dept Clin & Expt Sci, Div Gastroenterol & Hepatol, Linköping, Sweden..
Sodra Alvsborgs Hosp, Dept Internal Med, Borås, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden.;Linköping Univ, Dept Surg, Linköping, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
Örebro Univ, Fac Med & Hlth, Dept Gastroenterol, Örebro, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
Show others...
2023 (English)In: Clinical and Translational Gastroenterology, E-ISSN 2155-384X, Vol. 14, no 8, article id e00605Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION:
Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performance in relation to other novel fecal markers of various cellular origins is unknown.
METHODS:
We performed a prospective multicenter cohort study and included patients with active IBD who provided a fecal sample at initiation of biological therapy. Levels of FC, myeloperoxidase (MPO), human neutrophil lipocalin (HNL), and eosinophil-derived neurotoxin (EDN) were analyzed and related to clinical remission status at 3 months. Changes in levels of markers at 3 months were calculated, and the impact of concomitant use of corticosteroids at baseline was estimated.
RESULTS:
In patients achieving clinical remission (n = 27), a decrease in levels of FC (P = 0.005), MPO (P < 0.001), HNL (P < 0.001), and EDN (P < 0.001) was observed, whereas no significant decrease was seen in patients not achieving remission (n = 39). There was a significant difference in the change in the level of MPO (P = 0.01) and HNL (P = 0.02) between patients achieving clinical remission and those who did not, but changes in FC and EDN could not differentiate between these groups. Patients with concomitant systemic corticosteroids at inclusion had lower levels of HNL (P = 0.01) and EDN (P < 0.001) at baseline, compared with patients without corticosteroids.
DISCUSSION:
Fecal MPO, HNL, and EDN are all promising biomarkers for assessing the treatment outcome of biologics in patients with IBD. Fecal levels of EDN and HNL are significantly affected by corticosteroids indicating a greater sensitivity to the effects of corticosteroids compared with levels of FC and MPO.
Place, publisher, year, edition, pages
Wolters Kluwer, 2023
Keywords
inflammatory bowel disease, fecal biomarkers, biological therapy
National Category
Gastroenterology and Hepatology Immunology in the medical area
Identifiers
urn:nbn:se:uu:diva-524612 (URN)10.14309/ctg.0000000000000605 (DOI)001158085800005 ()37256716 (PubMedID)
Funder
Swedish Foundation for Strategic Research, RB13-016Uppsala University
2024-03-112024-03-112025-02-11Bibliographically approved